Skip to main content
Trending storyContinuously updated

Atlas Bio exits stealth with $12.5M for AI trial simulation

2 reports2 report sources2 hours agoUpdate

Get up to speed on this story

AI Summary

Basel-based Atlas Bio has come out of stealth with $12.5M in total funding to simulate Phase II drug trials using AI. The total includes a $10M seed round led by Creandum and a $2.5M pre-seed round led by First Momentum Ventures and LEA Partners. The company, founded in 2024 by former autonomous-driving engineers, says it expects its first trial results about six weeks after the October 27 announcement.

AI-generated from reports · 6 minutes agoUpdate

Latest updatesOct 27 21:00
Atlas Bio raises $12.5M to simulate Phase II drug trials with AI

Report timeline

Follow the reports to understand different sides of the story.

Oct 27
  1. Tech Funding NewsTop Deals
    Atlas Bio raises $12.5M to simulate Phase II drug trials with AI

    Atlas Bio, a Basel-based startup founded in 2024 by former autonomous-driving engineers.

  2. Tech.euTop Deals
    Atlas Bio raises $12.5M to simulate clinical trials with AI

    Swiss tech-bio startup Atlas Bio launched from stealth with $12.5M total funding.

Trend for this story

Not enough continuous observation data yet; trend chart is not drawn for now.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing